

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Keith BIGGADIKE et al.

Serial No.: 10/564,299

Art Unit: 1614

Filing Date: September 12, 2006

Examiner: To be assigned

For: *Specific Glucocorticosteroid Compounds
Having Anti-Inflammatory Activity*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed

☐ Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))

☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☒ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☒ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



James P. Riek
Attorney of Record
Registration No. 39,009

Date: 6-11-2007
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8022
Facsimile: (919) 483-7988

| | | | |
|---|--|---------------------|------------------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | SERIAL NO. | 10/564,299 |
| | | FILING DATE | September 12, 2006 |
| | | APPLICANT | Keith Biggadike et al. |
| | | GROUP | 1614 |
| | | EXAMINER | To be assigned |
| | | ATTORNEY DOCKET NO. | PB60925USw |

U.S. PATENT DOCUMENTS

| Examiner Initials | Patent Number | Issue Date | Name | Class | Subclass | Filing Date If Appropriate |
|-------------------|---------------|------------|-----------------|-------|----------|----------------------------|
| | 1. 5,552,438 | 09/03/1996 | CHRISTENSEN, IV | | | |
| | 2. 6,172,054 | 01/09/2001 | CLARK | | | |
| | 3. 6,245,804 | 06/12/2001 | LEHMANN et al. | | | |
| | 4. 6,395,738 | 05/28/2002 | OHSHIMA et al. | | | |
| | 5. 6,897,224 | 05/24/2005 | JAROCH et al. | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

Continue on page

FOREIGN PATENT DOCUMENTS

| | Document Number | Publication Date | Country | Class | Subclass | Translation Yes No |
|--|------------------|------------------|---------|-------|----------|-------------------------|
| | 6. GB 1384372 | 02/19/1975 | GB | | | |
| | 7. GB 2079755 | 01/27/1982 | GB | | | |
| | 8. GB 2137206 | 10/03/1984 | GB | | | |
| | 9. WO 89/03396 | 04/20/1989 | PCT | | | |
| | 10. WO 93/13055 | 07/08/1993 | PCT | | | |
| | 11. WO 95/34534 | 12/21/1995 | PCT | | | |
| | 12. WO 97/41867 | 11/13/1997 | PCT | | | |
| | 13. WO 98/30537 | 07/16/1998 | PCT | | | |
| | 14. WO 98/54159 | 12/03/1998 | PCT | | | X |
| | 15. WO 99/16766 | 04/08/1999 | PCT | | | X |
| | 16. WO 99/32127 | 07/01/1999 | PCT | | | |
| | 17. WO 99/47505 | 09/23/1999 | PCT | | | |
| | 18. WO 99/62875 | 12/09/1999 | PCT | | | |
| | 19. WO 00/66590 | 11/09/2000 | PCT | | | |
| | 20. WO 01/04118 | 01/18/2001 | PCT | | | |
| | 21. WO 01/10143 | 02/08/2001 | PCT | | | |
| | 22. WO 01/16128 | 03/08/2001 | PCT | | | |
| | 23. WO 01/42193 | 06/14/2001 | PCT | | | |
| | 24. WO 02/02565 | 01/10/2002 | PCT | | | |
| | 25. WO 02/26722 | 04/04/2002 | PCT | | | |
| | 26. WO 02/40030 | 05/23/2002 | PCT | | | |
| | 27. WO 02/50021 | 06/27/2002 | PCT | | | |
| | 28. WO 02/66422 | 08/29/2002 | PCT | | | |
| | 29. WO 02/70490 | 09/12/2002 | PCT | | | |
| | 30. WO 02/76933 | 10/03/2002 | PCT | | | |
| | 31. WO 03/08277 | 01/30/2003 | PCT | | | |
| | 32. WO 03/024439 | 03/27/2003 | PCT | | | |
| | 33. WO 03/042160 | 05/23/2003 | PCT | | | |
| | 34. WO 03/059899 | 07/24/2003 | PCT | | | |

Continue on page 2

| | |
|---|-----------------|
| EXAMINER | DATE CONSIDERED |
| EXAMINER. Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant. | |

| | | | | | | | |
|---|-----|---|------------------|---------------------|-----------------|------------------------|-------------------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | | | SERIAL NO. | | 10/564,299 | |
| | | | | FILING DATE | | September 12, 2006 | |
| | | | | APPLICANT | | Keith Biggadike et al. | |
| | | | | GROUP | | 1614 | |
| | | | | EXAMINER | | To be assigned | |
| | | | | ATTORNEY DOCKET NO. | | PB60925U/Sw | |
| FOREIGN PATENT DOCUMENTS (Cont'd) | | | | | | | |
| | | Document Number | Publication Date | Country | Class | Subclass | Translation Yes No |
| | 35. | WO 03/061651 | 07/31/2003 | PCT | | | |
| | 36. | WO 03/072539 | 09/04/2003 | PCT | | | |
| | 37. | WO 03/082280 | 10/09/2003 | PCT | | | |
| | 38. | WO 03/082787 | 10/09/2003 | PCT | | | |
| | 39. | WO 03/082827 | 10/09/2003 | PCT | | | X |
| | 40. | WO 03/086294 | 10/23/2003 | PCT | | | |
| | 41. | WO 03/091204 | 11/06/2003 | PCT | | | |
| | 42. | WO 03/101932 | 12/11/2003 | PCT | | | |
| | 43. | WO 03/104195 | 12/18/2003 | PCT | | | |
| | 44. | WO 04/005229 | 01/15/2004 | PCT | | | |
| | 45. | WO 04/009016 | 01/29/2004 | PCT | | | |
| | 46. | WO 04/009017 | 01/29/2004 | PCT | | | |
| | 47. | WO 04/016578 | 02/26/2004 | PCT | | | |
| | 48. | WO 04/018429 | 03/04/2004 | PCT | | | |
| | 49. | WO 04/022547 | 03/18/2004 | PCT | | | |
| | 50. | WO 04/024728 | 03/25/2004 | PCT | | | |
| | 51. | WO 04/026248 | 04/01/2004 | PCT | | | |
| | 52. | WO 04/037768 | 05/06/2004 | PCT | | | |
| | 53. | WO 04/037773 | 05/06/2004 | PCT | | | |
| | 54. | WO 04/037807 | 05/06/2004 | PCT | | | |
| | 55. | WO 04/039762 | 05/13/2004 | PCT | | | |
| | 56. | WO 04/039766 | 05/13/2004 | PCT | | | |
| | 57. | WO 04/056823 | 07/08/2004 | PCT | | | |
| | 58. | WO 04/103998 | 12/02/2004 | PCT | | | |
| Continue on page | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) | | | | | | | |
| | 59. | Austin et al., "Mometasone furoate is a less specific glucocorticoid than fluticasone propionate," <i>Eur Resp J</i> 20(6):1386-1392 (Dec. 2002). | | | | | |
| | 60. | Fuji et al., "Novel phosphodiesterase 4 inhibitor T-440 reverses and prevents human bronchial contraction induced by allergen," <i>J Pharmacol Exp Ther</i> 284(1):162 (1998). | | | | | |
| | 61. | Landells et al., "Oral administration of the phosphodiesterase (PDE)4 inhibitor, V11294A inhibits ex-vivo agonist-induced-cell activation," <i>Eur Resp J (Ann Cong Eur Resp Soc, Geneva)</i> 12(Suppl. 28) Abstr P2393 (Sep. 1998). | | | | | |
| | 62. | RACHWAL et al., "Chemistry of loteprednol etabonate and related steroids. II. Reactions at ring C' and NMR structural studies of the resulting compounds," <i>Steroids</i> 63 (4):193-201 (1998) | | | | | |
| | 63. | Ray et al., "Induction of the E-selectin promoter by interleukin 1 and tumour necrosis factor α , and inhibition by glucocorticoids," <i>Biochem J</i> 328:707-715 (Dec. 1997). | | | | | |
| | 64. | Phillips, GH et al., "Synthesis and structure activity Relationships in a series of Anti-inflammatory Corticosteroid Analogs. Halomethyl Androstane - 17B-carbothioates and -17B-carboselenoates," <i>Journal of Medicinal Chemistry</i> 1994, 37, 3717-3729. | | | | | |
| Continue on page | | | | | | | |
| EXAMINER | | | | | DATE CONSIDERED | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant. | | | | | | | |